Crescent Biopharma, Inc.
CBIO
$18.00
$0.724.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | ||
|---|---|---|---|---|---|
| Net Income | 74.80% | -275.49% | -12.93% | -43.85% | |
| Total Depreciation and Amortization | 18.52% | 92.86% | 1,300.00% | -- | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | -95.04% | 3,978.85% | -72.44% | 513.00% | |
| Change in Net Operating Assets | 152.36% | -487.84% | 329.63% | -170.45% | |
| Cash from Operations | 66.58% | -52.46% | -6.93% | -51.16% | |
| Capital Expenditure | 23.83% | 67.06% | -318.57% | -- | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | 88.89% | -- | -- | -- | |
| Cash from Investing | 88.71% | -12,219.62% | -318.57% | -- | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -- | -- | -- | 2,885,520.00% | |
| Repurchase of Common Stock | -- | 100.00% | -608.47% | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -100.00% | 285.11% | |
| Cash from Financing | -103.88% | 14,363.16% | -100.85% | 9,983.18% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -130.06% | 512.44% | -114.87% | 1,156.35% | |